[Diamond Biofund] Announcement of Fulfillment of Commitments Made at the Time of Initial Public Offering and Subsequent Execution Status
Diamond Biofund announced its compliance with commitments made during its IPO, including the disposal of shares in Aimed Bio by October 25, 113, and the implementation of corporate governance reforms such as establishing a nomination committee and increasing independent director representation.
📋 Article Processing Timeline
- 📰 Published: April 9, 2026 at 09:00
- 🔍 Collected: April 10, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: April 19, 2026 at 03:56 (211h 56m after Collected)
1. Date of Fact Occurrence: 115/04/09
2. Company Name: Diamond Biofund Investment Co., Ltd.
3. Relationship with Company (Enter 'This Company' or 'Subsidiary'): This Company
4. Proportion of Mutual Shareholding: Not applicable
5. Reason for Occurrence:
In accordance with the regulations of the Taiwan Stock Exchange Corporation, pursuant to Letter No. 1121802934 dated June 29, 112, the company hereby announces the commitments made at the time of its initial public offering and their subsequent execution status:
(I) Disclosure in the 'Special Matters' section of the prospectus:
1. Reasonableness of performance changes over the last three fiscal years and up to the latest period.
2. Reasons for, legality of, reasonableness of, operational risks of, and countermeasures for mutual shareholding with invested company Aimed Bio Co., Ltd.
(II) To mitigate the impact of mutual shareholding on profit and loss, the company will cease increasing its holdings in Aimed Bio Co., Ltd. and will dispose of all its shares in Aimed Bio Co., Ltd. by December 31, 113.
(III) Insider individuals and top ten shareholders commit to extending the lock-up period for shares. After two years from listing, one-quarter can be redeemed every six months, and all shares can be redeemed after four years. Shares obtained by the aforementioned individuals after listing and before the end of the lock-up period, due to profit capitalization or other reasons (such as the exercise of employee stock options and employee bonuses), must be submitted for centralized custody and can only be redeemed on the last redemption date.
(IV) A 'Nomination Committee' will be established after listing, and independent directors will be elected at the shareholders' meeting in 113 to constitute more than two-thirds of the total board seats.
(V) The prospectus shall enhance disclosure of the following matters:
1. Characteristics and investment risks of biotech venture capital companies (including but not limited to the lack of transparency in the fair value of their invested companies, which are unlisted or not publicly issued, and the potential for significant changes in their investment portfolio, etc.).
2. The company's future investment targets, policies, strategies, scope, regions, decision-making processes, and principles and methods for exercising voting rights, etc.
3. The cover page shall state: 'This company operates as a venture capital firm primarily investing in the biotechnology industry. The development cycle for biotechnology is long, requires high investment, and success is not guaranteed. Investors are urged to pay special attention to and read the contents of this company's prospectus carefully and invest prudently.'
4. The section on industry, operational, and other significant risks shall state: '...The company's primary investments are in biotechnology stocks, whose share prices and fair values are significantly affected by R&D outcomes, resulting in substantial volatility. Therefore, a decline in fair value may lead to negative operating revenue for the company...'
(VI) The Board of Directors has approved amendments to the following investment business-related regulations: 'Asset Acquisition or Disposal Procedures,' 'Investment Business Operating Rules,' and 'Investment Business Risk Control Rules.' The 'Asset Acquisition or Disposal Procedures' shall also be submitted for approval at the nearest shareholders' meeting:
1. The Chairman's authority limit for approving transactions will be reduced from NT$500 million to NT$300 million. Any transaction for the acquisition or disposal of investments exceeding NT$300 million must be approved by the Investment Review Committee, the Audit Committee, and the Board of Directors. The aforementioned amount shall be calculated cumulatively, including the consolidated calculation of the parent company and its subsidiaries (if any).
2. Establish clear exit mechanisms for investment targets:
(1) Notification and Evaluation: For listed and OTC investment targets where unrealized profits reach three times the original investment cost or unrealized losses reach 30% of the original investment cost, the investment department shall issue a notification or warning and propose a holding or disposal evaluation plan. If the evaluation results in disposal, it shall be executed according to the approval authority (transactions within NT$300 million (inclusive) with projected profits will be approved by the Chairman; transactions exceeding NT$300 million with projected profits require approval from the Investment Review Committee, Audit Committee, and Board of Directors). If the decision is to continue holding, it must be reported to the Investment Review Committee for agreement.
(2) Mandatory Exit: If the unrealized profits reach five times the original investment cost or unrealized losses reach 50% of the original investment cost, mandatory exit conditions apply. The investment department shall issue a notification or warning and propose a disposal plan to be executed according to the approval authority (same as above). If the resolution is not to dispose, the exceptional management plan must be submitted to the Investment Review Committee, Audit Committee, and Board of Directors for resolution and reported to the Board of Directors regularly on the execution status.
(VII) Post-listing information disclosure will be as follows:
1. Daily announcement of the fair value of investment targets that are listed/OTC/emerging stocks on the company's official website.
2. Monthly announcement on the company's official website and via major news releases regarding changes in the number of shares and fair value of 'all investment targets,' the company's net asset value per share, and cash and cash equivalents.
3. Quarterly investor relations conferences to explain the company's financial and business status and revenue recognition characteristics.
4. If the company's operating revenue shows negative figures for three consecutive months, a major announcement should be issued to warn investors.
6. Countermeasures:
(I) All relevant information has been appropriately disclosed in the prospectus 'Prospectus for Initial Public Offering of New Shares Through Public Offering and Listing' printed in September 112. Please refer to the Market Observation Post System for details.
(II) Completed the disposal of all shares held in Aimed Bio Co., Ltd. on October 25, 113.
2. Company Name: Diamond Biofund Investment Co., Ltd.
3. Relationship with Company (Enter 'This Company' or 'Subsidiary'): This Company
4. Proportion of Mutual Shareholding: Not applicable
5. Reason for Occurrence:
In accordance with the regulations of the Taiwan Stock Exchange Corporation, pursuant to Letter No. 1121802934 dated June 29, 112, the company hereby announces the commitments made at the time of its initial public offering and their subsequent execution status:
(I) Disclosure in the 'Special Matters' section of the prospectus:
1. Reasonableness of performance changes over the last three fiscal years and up to the latest period.
2. Reasons for, legality of, reasonableness of, operational risks of, and countermeasures for mutual shareholding with invested company Aimed Bio Co., Ltd.
(II) To mitigate the impact of mutual shareholding on profit and loss, the company will cease increasing its holdings in Aimed Bio Co., Ltd. and will dispose of all its shares in Aimed Bio Co., Ltd. by December 31, 113.
(III) Insider individuals and top ten shareholders commit to extending the lock-up period for shares. After two years from listing, one-quarter can be redeemed every six months, and all shares can be redeemed after four years. Shares obtained by the aforementioned individuals after listing and before the end of the lock-up period, due to profit capitalization or other reasons (such as the exercise of employee stock options and employee bonuses), must be submitted for centralized custody and can only be redeemed on the last redemption date.
(IV) A 'Nomination Committee' will be established after listing, and independent directors will be elected at the shareholders' meeting in 113 to constitute more than two-thirds of the total board seats.
(V) The prospectus shall enhance disclosure of the following matters:
1. Characteristics and investment risks of biotech venture capital companies (including but not limited to the lack of transparency in the fair value of their invested companies, which are unlisted or not publicly issued, and the potential for significant changes in their investment portfolio, etc.).
2. The company's future investment targets, policies, strategies, scope, regions, decision-making processes, and principles and methods for exercising voting rights, etc.
3. The cover page shall state: 'This company operates as a venture capital firm primarily investing in the biotechnology industry. The development cycle for biotechnology is long, requires high investment, and success is not guaranteed. Investors are urged to pay special attention to and read the contents of this company's prospectus carefully and invest prudently.'
4. The section on industry, operational, and other significant risks shall state: '...The company's primary investments are in biotechnology stocks, whose share prices and fair values are significantly affected by R&D outcomes, resulting in substantial volatility. Therefore, a decline in fair value may lead to negative operating revenue for the company...'
(VI) The Board of Directors has approved amendments to the following investment business-related regulations: 'Asset Acquisition or Disposal Procedures,' 'Investment Business Operating Rules,' and 'Investment Business Risk Control Rules.' The 'Asset Acquisition or Disposal Procedures' shall also be submitted for approval at the nearest shareholders' meeting:
1. The Chairman's authority limit for approving transactions will be reduced from NT$500 million to NT$300 million. Any transaction for the acquisition or disposal of investments exceeding NT$300 million must be approved by the Investment Review Committee, the Audit Committee, and the Board of Directors. The aforementioned amount shall be calculated cumulatively, including the consolidated calculation of the parent company and its subsidiaries (if any).
2. Establish clear exit mechanisms for investment targets:
(1) Notification and Evaluation: For listed and OTC investment targets where unrealized profits reach three times the original investment cost or unrealized losses reach 30% of the original investment cost, the investment department shall issue a notification or warning and propose a holding or disposal evaluation plan. If the evaluation results in disposal, it shall be executed according to the approval authority (transactions within NT$300 million (inclusive) with projected profits will be approved by the Chairman; transactions exceeding NT$300 million with projected profits require approval from the Investment Review Committee, Audit Committee, and Board of Directors). If the decision is to continue holding, it must be reported to the Investment Review Committee for agreement.
(2) Mandatory Exit: If the unrealized profits reach five times the original investment cost or unrealized losses reach 50% of the original investment cost, mandatory exit conditions apply. The investment department shall issue a notification or warning and propose a disposal plan to be executed according to the approval authority (same as above). If the resolution is not to dispose, the exceptional management plan must be submitted to the Investment Review Committee, Audit Committee, and Board of Directors for resolution and reported to the Board of Directors regularly on the execution status.
(VII) Post-listing information disclosure will be as follows:
1. Daily announcement of the fair value of investment targets that are listed/OTC/emerging stocks on the company's official website.
2. Monthly announcement on the company's official website and via major news releases regarding changes in the number of shares and fair value of 'all investment targets,' the company's net asset value per share, and cash and cash equivalents.
3. Quarterly investor relations conferences to explain the company's financial and business status and revenue recognition characteristics.
4. If the company's operating revenue shows negative figures for three consecutive months, a major announcement should be issued to warn investors.
6. Countermeasures:
(I) All relevant information has been appropriately disclosed in the prospectus 'Prospectus for Initial Public Offering of New Shares Through Public Offering and Listing' printed in September 112. Please refer to the Market Observation Post System for details.
(II) Completed the disposal of all shares held in Aimed Bio Co., Ltd. on October 25, 113.